Biotech

All Articles

Lykos will certainly ask FDA to reexamine its own selection complying with rejection of MDMA therapy for post-traumatic stress disorder

.Following a bad showing for Lykos Therapies' MDMA prospect for trauma at a current FDA consultatory...

AN 2 one-halfs roll call, stops phase 3 test after records disappoint

.AN2 Therapies is reconsidering its own service in response to uninspired midphase data, pledging to...

Merck pays for $700M for bispecific, spying autoimmune position as well as opportunity to challenge Amgen in cancer cells

.Merck &amp Co. is paying $700 million upfront to test Amgen in a blood stream cancer market. The de...

Gilead spends J&ampJ $320M to exit licensing offer for seladelpar

.With Gilead Sciences on the verge of an FDA choice for its liver disease medicine seladelpar, the f...

' All hands on deck' at Lilly as peers target being overweight market

.CEO David Ricks can easily view the business setting up tents at basecamp behind Eli Lilly in an at...

Entero laying off staff, leaving workplace and also stopping R&ampD

.Bed mattress Liquidators has actually turned Entero Rehabs white as a slab. The lender purchased En...

Exelixis loses ADC after choosing it is actually no suit for Tivdak

.Exelixis is actually quiting on its own cells aspect (TF)- targeting antibody-drug conjugate after ...

Relay dislikes SHP2 prevention after Genentech leaves behind

.Three weeks after Roche's Genentech device bowed out an SHP2 inhibitor treaty, Relay Therapy has co...

Stoke's Dravet disorder med discharged of partial medical hold

.Stoke Therapeutics' Dravet syndrome medication has been actually devoid of a partial hold, getting ...

Fierce Biotech's Gabrielle Masson shows Tough 15 at NYSE

.Fierce Biotech Partner Editor Gabrielle Masson showed the 2024 course of Tough 15 champions on the ...